Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM).’ The study aims to determine how common endogenous hypercortisolism (eHC) is among patients with resistant hypertension (rHTN). This research is significant as it could unveil new insights into managing hypertension that does not respond to standard treatments.
The study is non-interventional, meaning it does not involve testing new drugs or treatments. Instead, it focuses on observing and collecting data from patients. Participants undergo a series of tests, including a dexamethasone suppression test, to assess cortisol levels and determine the presence of eHC.
This observational study follows a cohort model with a cross-sectional time perspective. It involves approximately 1,000 patients across 45 sites in the United States. The study does not involve any masking or allocation as it is purely observational.
The study began on March 28, 2025, with an update submitted on June 24, 2025. These dates are crucial as they mark the progress and ongoing nature of the study, which is currently recruiting participants.
The results of this study could impact Corcept Therapeutics’ stock performance by potentially expanding its market reach in hypertension treatment. Investors should watch for updates, as positive findings could improve investor sentiment and position Corcept favorably against competitors in the hypertension treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.